| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
52,750,000 |
| Market
Cap: |
263.75(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.17 - $26.9 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 17.7 |
| Insider 6 Months : 17.7 |
| Insider 3/6 Months : 35.1 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Treace Medical Concepts is a medical technology company engaging in the surgical treatment of Hallux Valgus (commonly known as bunions). Co. has developed the proprietary Lapiplasty 3D Bunion Correction System, a combination of instruments, implants and surgical methods designed to improve the inconsistent clinical outcomes of approaches to bunion surgery. In addition, Co. provides other instrumentation and implants for use in the Lapiplasty Procedure or other ancillary procedures with bunion surgery. Co. has expanded its offerings with the Adductoplasty™ Midfoot Correction System, designed for reproducible correction of the midfoot to provide further support to Hallux Valgus patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
803,000 |
803,000 |
803,000 |
896,025 |
| Total Buy Value |
$3,652,501 |
$3,652,501 |
$3,652,501 |
$5,516,603 |
| Total People Bought |
5 |
5 |
5 |
7 |
| Total Buy Transactions |
8 |
8 |
8 |
16 |
| Total Shares Sold |
0 |
0 |
1,115,821 |
3,425,410 |
| Total Sell Value |
$0 |
$0 |
$29,553,643 |
$81,265,029 |
| Total People Sold |
0 |
0 |
2 |
10 |
| Total Sell Transactions |
0 |
0 |
3 |
107 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Treace James T |
Director |
– • – |
2021-12-20 |
4 |
A |
$0.00 |
$0 |
D/D |
406,183 |
1,461,441 |
|
- |
|
| Treace James T |
Director |
– • – |
2021-12-20 |
4 |
A |
$0.00 |
$0 |
I/I |
406,183 |
1,006,183 |
|
- |
|
| Treace James T |
Director |
– • – |
2021-12-20 |
4 |
AS |
$0.00 |
$0 |
I/I |
(1,353,944) |
58,883 |
|
22% |
|
| Treace James T |
Director |
– • – |
2021-12-20 |
4 |
AS |
$15.69 |
$253,107 |
I/I |
(16,119) |
1,412,827 |
|
22% |
|
| Treace John T. |
Chief Executive Officer |
• • • |
2021-12-20 |
4 |
AS |
$15.74 |
$360,897 |
D/D |
(22,911) |
5,564,669 |
|
22% |
|
| Treace James T |
Director |
– • – |
2021-12-15 |
4 |
AS |
$16.06 |
$1,204,643 |
D/D |
(75,000) |
1,055,258 |
|
20% |
|
| Treace John T. |
Chief Executive Officer |
• • • |
2021-11-24 |
4 |
AS |
$17.66 |
$999,284 |
D/D |
(56,000) |
5,587,580 |
|
13% |
|
| Treace John T. |
Chief Executive Officer |
• • • |
2021-11-23 |
4 |
AS |
$17.37 |
$974,687 |
D/D |
(56,000) |
5,643,580 |
|
10% |
|
| Treace John T. |
Chief Executive Officer |
• • • |
2021-11-22 |
4 |
AS |
$18.34 |
$972,517 |
D/D |
(53,000) |
5,699,580 |
|
6% |
|
| Treace James T |
Director |
– • – |
2021-11-17 |
4 |
AS |
$20.33 |
$508,250 |
D/D |
(25,000) |
2,130,258 |
|
-6% |
|
| Treace James T |
Director |
– • – |
2021-11-16 |
4 |
AS |
$20.86 |
$521,500 |
D/D |
(25,000) |
2,155,258 |
|
-11% |
|
| Treace James T |
Director |
– • – |
2021-11-15 |
4 |
AS |
$20.41 |
$515,765 |
D/D |
(25,000) |
2,180,258 |
|
-5% |
|
| Treace James T |
Director |
– • – |
2021-11-12 |
4 |
GD |
$0.00 |
$0 |
D/D |
600,000 |
1,130,258 |
|
- |
|
| Scanlan Sean F. |
SVP, Marketing |
• – – |
2021-11-10 |
4 |
AS |
$21.53 |
$538,431 |
D/D |
(25,000) |
0 |
|
-12% |
|
| Scanlan Sean F. |
SVP, Marketing |
• – – |
2021-11-10 |
4 |
OE |
$1.57 |
$39,250 |
D/D |
25,000 |
25,000 |
|
- |
|
| Treace James T |
Director |
– • – |
2021-10-27 |
4 |
GD |
$0.00 |
$0 |
D/D |
400,000 |
1,730,258 |
|
- |
|
| Treace John T. |
Chief Executive Officer |
• • • |
2021-10-22 |
4 |
AS |
$20.74 |
$1,204,980 |
D/D |
(58,089) |
5,752,580 |
|
-16% |
|
| Treace John T. |
Chief Executive Officer |
• • • |
2021-10-21 |
4 |
AS |
$19.89 |
$1,581,123 |
D/D |
(76,084) |
5,810,669 |
|
3% |
|
| Timbie Thomas E |
Director |
– • – |
2021-10-20 |
4 |
AS |
$25.18 |
$281,244 |
I/I |
(11,171) |
2,249,069 |
|
-17% |
|
| Treace John T. |
Chief Executive Officer |
• • • |
2021-10-20 |
4 |
AS |
$24.79 |
$768,908 |
D/D |
(30,827) |
5,886,753 |
|
-17% |
|
| Ferguson Joe W. |
SVP, Research & Development |
• – – |
2021-10-06 |
4 |
OE |
$0.10 |
$30,864 |
D/D |
308,641 |
419,756 |
|
- |
|
| Timbie Thomas E |
Director |
– • – |
2021-09-07 |
4 |
GD |
$0.00 |
$0 |
I/I |
560,000 |
2,260,240 |
|
- |
|
| Treace John T. |
Chief Executive Officer |
• • • |
2021-09-07 |
4 |
A |
$0.00 |
$0 |
I/I |
408,816 |
408,816 |
|
- |
|
| Bakewell John K |
SVP, Research & Development |
• – – |
2021-04-27 |
4 |
A |
$0.00 |
$0 |
I/I |
342,300 |
342,300 |
|
- |
|
| Ferguson Joe W. |
SVP, Research & Development |
• – – |
2021-04-27 |
4 |
A |
$0.00 |
$0 |
I/I |
85,575 |
85,575 |
|
- |
|
278 Records found
|
|
Page 10 of 12 |
|
|
0.47 (10.38%) 
